Recent Developments

Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today announced the appointment of Robert R. Ruffolo, Jr., Ph.D., to its Board of Directors, effective … Continue reading

Posted in Recent Development News: Q3 - 2017, Recent Developments | Comments Off

Edge Therapeutics Announces Commercial Supply Agreement for EG- 1962 with Oakwood Laboratories

Edge Therapeutics, Inc.(Nasdaq:EDGE) today announced that it has entered into a supply agreement and an amended and restated development agreement with Oakwood Laboratories for the commercial manufacturing of EG-1962 for initial product launch and thereafter. EG-1962, an orphan drug and … Continue reading

Posted in Recent Development News: Q3 - 2017, Recent Developments | Comments Off

ROOT9B HOLDINGS ADDED TO RUSSELL MICROCAP® INDEX

- root9B Holdings Inc. (NASDAQ: RTNB), a leading provider of advanced cybersecurity products, services and training, has been added to the Russell Microcap® Index, effective today. Russell Investments reconstituted its family of U.S. indexes after the close of the U.S. … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

root9B Remains #1 on Cybersecurity 500 For 6th Consecutive Quarter

COLORADO SPRINGS, Colo., June 23, 2017 — In response to remaining #1 on the Cybersecurity 500 for six consecutive quarters, root9B’s Chief Executive Officer Eric Hipkins issued the following statement: “root9B’s continued #1 presence on the Cybersecurity 500 is a … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

root9B Releases Technical Analysis on Active Malware Campaign After Briefing Law Enforcement

root9B, a root9B Holdings Inc. (NASDAQ: RTNB) company, and leading provider of advanced cybersecurity products, services, and training, has released an in-depth technical analysis report on a newly identified active campaign targeting point-of-sale systems. The report provides technical details of … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

root9B Releases Technical Analysis on Active Malware Campaign After Briefing Law Enforcement

root9B, a root9B Holdings Inc. (NASDAQ: RTNB) company, and leading provider of advanced cybersecurity products, services, and training, has released an in-depth technical analysis report on a newly identified active campaign targeting point-of-sale systems. The report provides technical details of … Continue reading

Posted in Recent Developments | Comments Off

Edge Therapeutics to Participate in the JMP Securities Life Science Conference

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life threatening conditions, today announced that President and Chief Executive Officer Brian A. Leuthner will participate in the panel discussion “Hospital Drug Launches … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

Edge Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life threatening conditions, today announced that it received a product-specific pediatric waiver from the European Medicines Agency (EMA) for EG-1962, Edge’s lead product … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017

ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announces five poster presentations of new data from the CF-301 development program at the American Society … Continue reading

Posted in Recent Developments | Comments Off

ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia

ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the initiation of an international Phase 2 study evaluating its first-in-class lysin, CF-301, as a potential … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

root9B Holdings Names Eric Hipkins Chief Executive Officer

root9B Holdings, Inc. (Nasdaq: RTNB) (“RTNB”), a leading provider of Cybersecurity and Regulatory Risk Mitigation Services, today announced that its Board of Directors has appointed Eric Hipkins as Chief Executive Officer effective May 25, 2017.

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

ContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave

ContraFect Corporation (NASDAQ: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company’s Chief Executive Officer and Chairman of … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off